Skip to main content
Fig. 2 | BMC Veterinary Research

Fig. 2

From: Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation

Fig. 2

Pimobendan (PIMO) prevents mitral regurgitation (MR)-induced myocardial dysfunction assessed by echocardiography. (A) Left ventricular internal diameter at end-diastole (LVIDd), (B) left ventricular internal diameter at end-systole (LVIDs), (C) ejection fraction (EF), (D), end-diastolic volume, (E) end-systolic volume, and (F) cardiac output (CO) are shown for each group. Data are presented as mean ± standard error of mean (SEM). Two-way ANOVA with Tukey’s post hoc test for the analysis of group differences. *P < 0.05 for differences among groups and between timepoints. BL = At the baseline; End = At the end of the experiment

Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us